Etigilimab represents a highly specialized humanized IgG1 monoclonal antibody specifically engineered to target the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) with exceptional binding affinity and selectivity. It effectively facilitates the measurable blockade of the TIGIT/CD155 (PVR) inhibitory axis across various preclinical experimental models to evaluate the restoration of T-cell and NK-cell effector functions during strictly monitored laboratory observation periods and functional immune activation assays to ensure high experimental sensitivity.